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Clostridium difficile is a Gram-positive, spore-forming anaerobic 
bacillus that causes disease by producing cytotoxins. The clinical 
outcome depends on host immunity and the virulence of the 
toxin-producing strain.[1] C. difficile causes disease that ranges 
in severity from asymptomatic colonisation to severe diarrhoea, 
pseudomembranous colitis (PMC), toxic megacolon, colonic 
perforation and death.[2]
Over the last decade, there has been a dramatic increase in 
the incidence and severity of C. difficile-associated diarrhoea 
(CDAD), predominantly affecting Western countries. The striking 
change in epidemiology, clinical severity and case-fatality ratio 
is attributable in part to the emergence of a strain, identified 
as the North American pulsed-field type 1 (NAP1), referred to 
more commonly in Europe as Type 027. This hypervirulent strain 
produces increased amounts of toxins and is resistant to the 
fluoroquinolones.[3]
 Data regarding the burden of CDAD in southern Africa are 
limited. The magnitude of C. difficile infection in South African 
hospitals is not known and it is also unclear what proportion of 
CDAD is community-acquired (CA-CDAD). Therefore, the aims of 
this study were to investigate the incidence of CDAD in a tertiary 
referral hospital, to evaluate associated risk factors and effect on 
patient morbidity and mortality, to report on the presence of NAP1 
and to determine the percentage of CA-CDAD.
Methods
The study was conducted at Groote Schuur Hospital (GSH), a 
943-bed tertiary referral hospital in Cape Town. All adult patients 
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Background and objectives. The aim of this study is to report the incidence of Clostridium difficile-associated disease (CDAD) in a tertiary-
care hospital in South Africa and to identify risk factors, assess patient outcomes and determine the impact of the hypervirulent strain of 
the organism referred to as North American pulsed-field type 1 (NAP1).
Methods. Adults who presented with diarrhoea over a period of 15 months were prospectively evaluated for CDAD using stool toxin 
enzyme immunoassay (EIA). Positive specimens were evaluated by PCR. Patient demographics, laboratory parameters and outcomes were 
analysed.
Results. CDAD was diagnosed in 59 (9.2%) of 643 patients (median age 39 years, IQR 30 - 55). Thirty-four (58%) were female. Recent 
antibiotic exposure was reported in 39 (66%), 27 (46%) had been hospitalised within 3 months, and 14 (24%) had concomitant inflammatory 
bowel disease (IBD). Nineteen (32%) had community-acquired CDAD (CA-CDAD). The annual incidence of hospital-acquired CDAD 
(HA-CDAD) was 8.7 cases/10 000 hospitalisations. Two cases of the hypervirulent strain NAP1 were identified. Seven (12%) patients 
underwent colectomy (OR 6.83; 95% CI 2.41 - 19.3). On logistic regression, only antibiotic exposure independently predicted for CDAD 
(OR 2.9; 95% CI 1.6 - 5.1). Three (16%) cases of CA-CDAD  reported antibiotic exposure (v. 90% of HA-CDAD, p<0.0001). Twelve (86%) 
patients had concomitant IBD (p<0.0001 v. HA-CDAD). CA-CDAD was significantly associated with antibiotic exposure (OR 0.04, 95% CI 
0.01 - 0.24) and IBD (OR 9.6, 95% CI 1.15 - 79.8).
Conclusion. The incidence of HA-CDAD in the South African setting is far lower than that reported in the West. While antibiotic use was 
a major risk factor for HA-CDAD, CA-CDAD was not associated with antibiotic therapy. Concurrent IBD was a predictor of CA-CDAD.
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admitted with diarrhoea, or who developed diarrhoea following 
admission for an unrelated condition, were evaluated prospectively 
over 15 months. Stool was tested for Toxin A using standard enzyme 
immunoassay (EIA). DNA was extracted from toxin-positive stool 
and subsequently subjected to real-time PCR. Demonstration of an 
18-base pair deletion of the tcd C gene, after amplification, indicated 
the presence of NAP1 strain.[4]
CDAD was diagnosed in cases with diarrhoea that were confirmed 
Toxin A positive. Patients with diarrhoea and demonstrable 
pseudomembranous colitis at endoscopy or at histopathology were 
also diagnosed as having CDAD. Persons under 18 years of age, and 
adults who provided formed stool samples to the laboratory, were 
excluded from the study.
The Centres for Disease Control (CDC)-recommended definitions 
for diarrhoea were adopted.[5] Diarrhoea was considered as hospital-
acquired if it had started more than 48 hours after admission, or if 
patients had resided in a long-term care facility, or if patients had 
been discharged from hospital or long-term care facility 14 days prior 
to presentation. CDAD was defined as diarrhoea that started before 
hospital admission or within 48 hours following admission.
The study was approved by the Ethics Committee of the University 
of Cape Town.
Statistical analysis
Statistical analysis was performed using Stata Statistical Software: 
Release 11 (StataCorp, College Station, USA). Continuous variables 
were expressed as medians and interquartile ranges (all variables 
in the final analysis had a non-Gaussian distribution). The Mann-
Whitney test was used to assess continuous variables, while the 
chi-square or Fisher’s exact test was used for categorical variables. 
Univariate analysis was performed initially for each variable. 
Variables differing between groups with a significance level of 
p<0.1 and other possible confounders identified a priori, were then 
entered into a series of multivariate logistic regression models. Age 
was treated as a categorical variable (<30 years, 30 - 49 years, 50 - 
64 years, ≥65 years). Models were built sequentially, starting with 
the variable most strongly associated with the outcome. A p-value 
≤0.05 was considered significant in the multivariate model. Some 
baseline variables that were significant on univariate analysis were 
omitted from the final models owing to collinearity. Different models 
were compared by using the likelihood ratio test, with significance 
determined at a p-value of 0.05.
Results
A total of 651 patients were enrolled. Eight were excluded owing to 
incomplete data, leaving 643 patients in the final analysis. Baseline 
characteristics are presented in Table 1. Fifty-nine (9.2%) individuals 
were diagnosed with CDAD, of whom 34 (58%) were female. The 
diagnosis was made by toxin detection in 51 (86.4%) patients. An 
additional 6 (10.2%) had features of pseudomembranous colitis at 
endoscopy and 2 (3.4%) at histopathology.
Among the CDAD cases, 39 (66%) had had recent antibiotic 
exposure (within 28 days of diagnosis) and 27 (46%) had been 
hospitalised within the previous 3 months; both variables were 
significantly associated with C. difficile infection on univariate 
analysis. Sixty-four per cent of patients with CDAD had been 
exposed to penicillin-based antibiotics — 26% to quinolones, 23% 
to carbapenems, 13% to cephalosporins and 3% to clindamycin. 
Although not statistically significant, there was a trend for 
increased use of proton pump inhibitors (PPIs) in subjects with 
CDAD compared with those without (49% v. 39%, p=0.089). 
No baseline laboratory marker was significantly associated with 
CDAD (Table 2). On logistic regression analysis (Table 3), only 
recent antibiotic exposure was identified as an independent 
predictor for CDAD (odds ratio (OR) 2.9; 95% CI 1.6 - 5.1).
HA-CDAD was diagnosed in 40 subjects (67.8%), 90% of whom 
had had recent exposure to antibiotics, giving an annual incidence of 
HA-CDAD of 8.7 cases per 10 000 hospitalisations. Of the 19 (32.2%) 
patients with CA-CDAD, only 3 (16%) reported recent exposure 
to antibiotics, compared with 90% with HA-CDAD (p<0.0001). 
Table 1. Baseline clinical characteristics
Variable C. diff +ve (n=59) C. diff -ve (n=584) p-value
Age (years), median (IQR) 39 (30 - 55) 42 (32 - 56.5) 0.200
Gender (female), n (%) 34 (58) 353 (61) 0.700
Ethnicity, n (%) 0.600
Black 16 (27) 179 (31)
White 5 (9) 75 (13)
Coloured 36 (61) 317 (54)
Asian 2 (3) 13 (2)
Co-morbid condition, n (%) 0.200
None 4 (7) 32 (5)
IBD 14 (24) 171 (29)
HIV 16 (27) 121 (21)
Diabetes 2 (3) 31 (5)
Malignancy 9 (15) 44 (8)
Other 14 (24) 185 (32)
Prior hospitalisation (within 90 days), n (%) 27 (46) 176 (30) 0.014
Recent antibiotic use (within 28 days), n (%) 39 (66) 229 (39) <0.0001
Concurrent PPI use, n (%) 29 (49) 221 (38) 0.089
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Fourteen (24%) patients with CDAD had concomitant IBD, 12 
(86%) of whom acquired the disease in the community (p<0.0001 
v. HA-CDAD). Table 4 compares the characteristics of HA-CDAD 
with CA-CDAD. Subjects with HA-CDAD had a significantly lower 
median baseline haemoglobin (8 g/dl v. 12 g/dl, p<0.0001) and serum 
albumin (24 g/l v. 41.5 g/l, p<0.0001) as well as significantly higher 
Table 3. Multivariate analysis of CDAD compared with controls
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Table 2. Baseline laboratory parameters
Variable C. diff +ve C. diff -ve p-value
Haemoglobin (g/dl), median (IQR) 9.7 (8.3 - 12.3) 10.6 (8.6 - 12.6) 0.1
White cell count (109/l), median (IQR) 8.5 (5.5 - 11.5) 9.5 (6.7 - 14.1) 0.06
Albumin (g/l), median (IQR) 31 (22 - 40) 31 (24 - 39) 0.6
Creatinine (µmol/l), median (IQR) 72.5 (50 - 116.5) 79 (58 - 127) 0.3
C-reactive protein (mg/l), median (IQR) 45.8 (8.9 - 157.4) 32.6 (9.1 - 112.1) 0.7
Table 4. Characteristics of HA-CDAD and CA-CDAD at diagnosis
HA-CDAD (N=40) CA-CDAD (N=19) p-value
Age (years), median (IQR) 36.5 (29 - 55) 41 (31 - 55) 0.710















Previous admission, n (%) 19 (48) 8 (42) 0.700
Recent antibiotic use, n (%) 36 (90) 3 (16) <0.0001
PPI use, n (%) 21 (53) 8 (42) 0.4600
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C-reactive protein levels (83.5 mg/l v. 4 mg/l, p=0.002) than subjects 
with CA-CDAD. There was no difference in baseline white blood 
cell counts or serum creatinine. On regression analysis, only recent 
antibiotic exposure (OR 0.04, 95% CI 0.01 - 0.24) and the presence 
of co-morbid IBD (OR 9.6, 95% CI 1.15 - 79.8) were predictors of 
CA- CDAD.
Seven (12%) patients with CDAD underwent colectomy (Table 
5), which on regression analysis was significantly associated with 
C. difficile infection (OR 6.83; 95% CI 2.41 - 19.3). However, no 
difference was observed in duration of hospital stay or the need for 
ICU care between subjects with and without C. difficile infection. 
There was no significant difference in mortality rates; the 30-day 
mortality rate for subjects with CDAD was 66.7%. Two (3.4%) 
cases of HA-CDAD owing to NAP1 were identified, both of which 
proved fatal.
Forty-four (74.6%) patients with CDAD were treated with 
metronidazole, 3 (5.2%) with oral vancomycin and 8 (13.4%) with 
a combination of oral vancomycin and metronidazole. Four (6.8%) 
patients received no antibiotics directed at C. difficile, 2 of whom 
underwent colectomy. Three (5.1%) patients had recurrent disease, 
all being successfully treated with antibiotics.
Discussion
Over the last decade, there has been concern about the rising incidence, 
disease severity and mortality associated with CDAD. The number of 
reported cases in the UK rose from 7 470 in 1994 to 43 682 in 2004. 
Stoke Mandeville Hospital reported 2 outbreaks between 2003 and 
2005 that resulted in 38 deaths.[6] Similarly in Quebec, Canada, the 
overall incidence of CDAD quadrupled in 2003, with a reported 30-day 
mortality of 6.9% in one study.[7] This markedly increased incidence has 
been attributed to the NAP1 strain of C. difficile that carries a mutation 
in the tcd C gene, a negative regulator of toxin  production, as a result 
of which the NAP1 strain produces more than 10 times the quantity of 
toxin than conventional strains.[3] NAP1 also produces an additional 
toxin, the so-called Binary toxin, which may act synergistically with 
Toxins A and B in causing disease.[8,9]
In southern Africa, data regarding C. difficile are scarce. Samie 
et al. undertook PCR detection of C. difficile in adults attending an 
outpatient department and in school-going children in the Vhembe 
District, South Africa.[10] They found a prevalence of 14% of C. difficile 
among study participants. However, the incidence of  CDAD in SA 
hospitals remains undetermined. In 2008, Lekalakala et al. reported 
on an increase in CDAD at their tertiary hospital in Pretoria and 
highlighted the importance of preventive measures involving close 
co-ordination between the laboratory and infection control teams.[11] 
Whether this apparent increase was caused by the NAP1 strain was 
not evaluated.
Overall, the annual incidence of HA-CDAD was 0.87 cases per 
1 000 hospitalisations, which is far lower than Western experience, 
where CDAD incidence rates of 7.4 cases per 1 000 admissions have 
been reported.[12] A possible explanation for this lower burden of 
disease may be the generally younger SA hospital patient population. 
The median age in our study was 41 years. However, when comparing 
patients 65 years and older with those 30 years and younger, an 
increased risk of developing CDAD was not observed (OR 0.7, 
95% CI 0.3 - 1.8). Another possible explanation may be the strict 
antimicrobial stewardship programme adopted at GSH, given that 
limiting the use of antibiotics has been shown to decrease the 
occurrence of CDAD.[13,14] The possibility remains that all cases of 
C. difficile might not have been identified, and the incidence of 
CDAD underestimated. Stool EIA for Toxin A lacks sensitivity and 
may miss cases producing toxin B only.[4,9] Another study limitation is 
that our hospital is a large, urban, tertiary-care teaching facility that 
may not be representative of other institutions.
Several risk factors render patients vulnerable to CDAD. The only 
independent variable in this study that was found to be strongly 
associated with CDAD, was recent exposure to antibiotics.[15-17] The 
hospital milieu serves as an important reservoir for resistant spores 
that may be passed on to individuals who then develop disease 
some time after exposure. Although univariate analysis suggested 
an increased risk of CDAD in subjects previously admitted to a 
healthcare facility within 90 days (p=0.014), significance was lost 
on multivariate analysis. SA is a high HIV-prevalent country, yet 
CDAD was not associated in this study with HIV infection. The 
relationship between CDAD and PPIs remains controversial,[18] but 
their use was shown not to significantly increase the risk for CDAD 
in this study.
While an elevated white cell count, hypo-albuminaemia, impaired 
renal function and raised inflammatory markers have been associated 
with severe CDAD, we did not find these parameters to be of significance. 
However, it bears noting that our control group also had serious illnesses 
with abnormal inflammatory and other markers. Similarly, the length 
of hospital stay, need for ICU admission, and mortality as outcome 
of disease did not reach significance. It is important to note that 1 in 
5 patients who developed CDAD during the course of their illness 
eventually died. Subjects with CDAD had an almost seven-fold increase 
in colectomy.
Several reports have highlighted an increased incidence of  CDAD 
in patients with IBD.[19-23] As in our study, it has been noted that IBD 
patients are particularly prone to CA-CDAD, even during remission 
and often without prior exposure to antibiotics.[24]
In conclusion: This is the first study, to our knowledge, that 
prospectively documents the impact of CDAD in a southern 
African hospital. The burden of disease is significantly lower than 
in the West, perhaps because the NAP1 strain has fortunately not 
reached the levels reported in countries recently experiencing 
severe outbreaks.
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Table 5. Length of hospital stay, need for ICU care and outcome of cases with CDAD and controls
Variable C. diff +ve C. diff -ve p-value
Duration of hospital stay (days), median (IQR) 19 (8 - 29) 17 (7 - 33) 0.700
ICU admission, n (%) 17 (37) 116 (28) 0.200
Colectomy, n (%) 7 (12) 13 (2) 0.001
Death, n (%) 12 (20) 92 (16) 0.400
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